Dermapharm Holding SE (ETR:DMP)

Dermapharm Holding SE Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	144.21	132.41	113.79	62.37	134.24	209.58
Depreciation & Amortization	35.81	35.45	34.93	33.38	23.7	20.66
Other Amortization	44.82	44.82	43.53	52.57	27.73	24.59
Loss (Gain) From Sale of Assets	0.15	1.17	2.72	-2.57	-0.2	-0.4
Asset Writedown & Restructuring Costs	11.74	11.74	8.32	15.82	43.48	9.91
Loss (Gain) on Equity Investments	-4.08	-4.34	-1.52	7.16	13.54	-0.32
Other Operating Activities	18.87	1.58	17.67	41.65	50.18	32.62
Change in Other Net Operating Assets	33.23	6.32	-18.06	9.04	-4.14	-46.27
Operating Cash Flow	284.74	229.15	201.38	219.42	288.53	250.37
Operating Cash Flow Growth	65.05%	13.79%	-8.22%	-23.95%	15.24%	90.98%

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Capital Expenditures	-43.89	-42.12	-38.24	-41.54	-39.01	-61.2
Sale of Property, Plant & Equipment	0.61	0.8	3.79	2.82	0.68	2.52
Cash Acquisitions	-48.96	-51.24	-	-389.4	-69.79	-22.51
Investment in Securities	-9.82	-9.82	0.3	7.95	3.93	-48.25
Other Investing Activities	4	4.13	4.53	4.74	5.18	0.1
Investing Cash Flow	-98.06	-98.24	-29.61	-415.43	-99.01	-129.35

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Long-Term Debt Issued	-	170	111.17	715	469.95	10
Long-Term Debt Repaid	-	-108.22	-219.3	-420.86	-541.19	-35.91
Net Debt Issued (Repaid)	32.71	61.78	-108.13	294.14	-71.24	-25.91
Common Dividends Paid	-48.46	-48.46	-47.38	-56.53	-116.83	-47.38
Other Financing Activities	-58.96	-59.43	-53.66	-33.07	-11.69	-7.69
Financing Cash Flow	-74.7	-46.11	-209.17	204.54	-199.77	-80.98

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Foreign Exchange Rate Adjustments	-1.24	-2.69	-0.04	-0	-0.15	1.07
Miscellaneous Cash Flow Adjustments	0	-	0	-0.83	-	0
Net Cash Flow	110.74	82.12	-37.44	7.7	-10.4	41.11

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	240.85	187.03	163.14	177.88	249.52	189.17
Free Cash Flow Growth	83.50%	14.64%	-8.29%	-28.71%	31.91%	109.48%
Free Cash Flow Margin	20.37%	15.87%	13.65%	15.46%	23.98%	19.70%
Free Cash Flow Per Share	4.47	3.47	3.03	3.30	4.63	3.51
Levered Free Cash Flow	160.29	100.96	99.52	106.43	218.88	127.86
Unlevered Free Cash Flow	189.34	131.38	136.03	140.78	226.59	133.38

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash Interest Paid	51.3	51.77	53.65	33.07	7.76	7.69
Cash Income Tax Paid	64.75	89.89	83.84	65.37	40.59	44.85
Change in Working Capital	33.23	6.32	-18.06	9.04	-4.14	-46.27

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 17, 2026

Data Sources Report a data error